All you need to get started with ETF selection and analysis. Create your account now →
Help us improve your experience. Please confirm your investor type:
Global ETF Survey 2026
The ETF Industry Is Evolving Fast
From AI infrastructure to active strategies, the ETF landscape is shifting. Share your perspective in the 7th Annual Global ETF Survey.
CURE ETF · Global X S&P Biotech ETF
The CURE Exchange Traded Fund (ETF) is provided by Global X. It is built to track an index: S&P Biotechnology Select Industry Index. The CURE ETF provides physical exposure, so by buying it you actually own parts of all the 143 underlying holdings. This share class generates a stream of income by distributing dividends.
Real-time data unavailable for CURE
LIVE
CLOSED
This fund is part ofUS Health Care1M perf.+13.74%
Last price
N/A
1M perf.
+27.36%
1M flows
+€924K
AuM
€32M
TER
0.45%
Rating
Not rated
CURE
N/A
Performance & flows
Segment for quartile rank
April 7, 2026 → July 3, 2026
Create a free account to view the flows graph
CURE
A$78.76
+24.57%
US Health Care
+12.88%
Historic performance and flows
| 1M | 3M | 1Y | 3Y | 5Y | MTD | QTD | YTD | ||
|---|---|---|---|---|---|---|---|---|---|
| Perf. | +27.36%  | +24.57% | +78.00% | +85.65% | +26.86%  | +1.34% | +1.34% | +26.43% | |
| Flows |
Key fund info
Segment for quartile rank
This ETF's jurisdiction country is not in your region (Europe and Middle East) ·
Main characteristics
More details
NAV
7/3/2026
A$78.76
1D NAV change
-0.02%
Dividend policy
Replication method
Direct (Physical)
Replication model
Full replication
No. of holdings
143
Inception date
11/8/2018
Jurisdiction
Australia
Distribution
Australia
Legal structure
Managed Investment Scheme
Base currency
AUD
Dividend distribution
Trailing 12-month distr. yield
Distribution frequency
Last distribution
Create a free account to view dividend distribution
Classification
Investment strategy
The Global X S&P Biotech ETF (CURE) seeks to invest in companies that potentially stand to benefit from further advances in the field of genomic science, such as companies involved in gene editing, genomic sequencing, genetic medicine/therapy, computational genomics, and biotechnology.
Tax optimisation
PEA
France
UK Reporting Status
United Kingdom
Create a free Trackinsight Essentials account to unlock insights
Access exclusive metrics and features to support your investment decisions.
New to Trackinsight?
For individual investors
Essentials
A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.
More fund data
Compare up to 3 funds
More screener filters
Choose your own screener columns from 100+ metrics
Lists for saving your research
Portfolio construction and analysis
Personal dashboard for live monitoring
For professional investors
Enterprise
Trackinsight Enterprise addresses the everyday operational, regulatory, and analytical pain points faced by professional and institutional ETF investors, from selection to execution.
Request a free trialSimilar ETFs in your region
XBI
1M perf.
+25.77%
TER
0.35%
PSCH
1M perf.
+21.42%
TER
0.29%
AAKG
1M perf.
+26.50%
TER
0.75%
XHE
1M perf.
+12.62%
TER
0.35%
XPH
1M perf.
+20.45%
TER
0.35%
Advertisement
Risk profile
Segment for quartile rank
Historical risk/return profile
| 3M | 1Y | 3Y | 5Y | |
|---|---|---|---|---|
| Returns | +24.57% | +78.00% | +85.65% | +26.86%  |
| Volatility | ||||
| Perf./Volatility | ||||
| Max drawdown |
Create a free account to view risk/return table
Synthetic Risk and Reward Indicator (SRRI)
UCITS
N/A
PRIIPS
N/A
More exposure metrics are available, exclusively in Trackinsight Enterprise
Exposure
Countries
USA
95.22%
Ireland
1.68%
United Kingdom
1.18%
Switzerland
1.18%
Unavailable
0.17%
Other
0.57%
Sectors
Healthcare
99.57%
Unavailable
0.17%
Other
0.26%
Diversification
Total weight of top 15 holdings out of 143
Top 15 holdings
Data as of May 31, 2026
Create a free account to view top holdings
Create a free account to view top holdings
More risk metrics are available, exclusively in Trackinsight Enterprise
Sustainability
Integrates ESG criteria
No
SDG
More sustainability metrics are available, exclusively in Trackinsight Enterprise
Issuer
Global X
Global X ID Card
Number of funds
516
Total AuM
€144.86B
Expense ratio range
0.02% - 2.06%
Average expense ratio
0.5711%
Top 5 funds by Global X
| AuM | ||
|---|---|---|
PAVE | Global X U.S. Infrastructure Development ETF | €12.48B |
AIQ | Global X Artificial Intelligence & Technology ETF | €8.64B |
QYLD | Global X Nasdaq 100 Covered Call ETF | €7.18B |
SHLD | Global X Defense Tech ETF | €6.35B |
COPX | Global X Copper Miners ETF | €6.24B |
Frequently asked questions about CURE
What does Global X S&P Biotech ETF, CURE, invest in?
CURE is a Passive ETF. This ETF provides exposure to Equally Weighted US Biotechnology Equities.
Which benchmark or index does CURE replicate?
CURE tracks the S&P Biotechnology Select Industry Net Total Return Index - USD, through a full replication replication method.
What is the Total Expense ratio (TER) of CURE?
CURE carries a total expense ratio (TER) of 0.45%, indicating the annual cost for holding the fund.
When was CURE launched?
CURE was introduced to the market on November 8, 2018. It trades on Australia
Who is the ETF issuer of CURE?
Global X S&P Biotech ETF, CURE, is provided by Global X. Learn more about Global X here.
What is the current assets under management (AUM) of CURE?
CURE oversees €32M in assets as of July 3, 2026.
How has CURE performed lately?
Based on data from July 3, 2026, CURE returned 27.36% over the past month, 24.57% over the last three months and 26.43% year-to-date.
What are the latest inflows or outflows for CURE?
As of July 3, 2026, CURE recorded net flows of +€935K over the last month and +€220K year-to-date.
Does CURE distribute dividends?
CURE follows a distributing dividend policy, meaning it pays out income to investors.
What are the main country or region exposures of CURE?
As of May 31, 2026, CURE has significant geographic allocations in USA, Ireland and United Kingdom.
In which sector or theme does CURE invest in?
As of May 31, 2026, CURE focuses largely on Healthcare.
How many securities does CURE hold and how diversified is it?
As of May 31, 2026, CURE holds 143 positions in its portfolio, with 22.04% of assets concentrated in its top 15 holdings.
What are the main positions in CURE?
As of May 31, 2026, CURE top three holdings include Revolution Medicines, Inc., Travere Therapeutics, Inc. and TG Therapeutics, Inc..
What is the base currency of CURE?
The base currency of CURE is AUD.
Advertisement
About Trackinsight
Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.
Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.
In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.
This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.
Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.
More about TrackinsightETF TOOLS
PLATFORM
ETF NEWS & RESEARCH
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy | Cookie policy | | Terms of use | Imprint
Privacy policy | Cookie policy | | Terms of use | Imprint
